University of Chicago Medical Center

Submitted by shatcher on
  • Chicago, IL
    Date of first commercial TAVR procedure performed*:
    Feb, 2012
    TAVR Total Commercial Volume
    Cumulative volume since program inception:
    582
    Average annual volume for reporting period:
    NA- Site did not meet the three-year period reporting requirements.
    30-Day Risk Adjusted TAVR Composite 1,2,3
    Reporting Period:
    October 1, 2020 through September 30, 2023
    Eligible procedures in reporting period:
    NA- Site did not meet the three-year period reporting requirements.
    TAVR 30 Day Composite Score**:
    NA- Site did not meet the three-year period reporting requirements.
    TAVR 30-Day Composite Rating**
    NA- Site did not meet the three-year period reporting requirements.

* Site may have performed non-commercial/research procedures prior to this date. Non-commercial and research procedures are not reported in the TVT Registry.

** Please view Ratings Explanation for detailed calculation and site rating information.

  • 30-Day Risk Adjustment TAVR Composite consists of six ordered categories based on the worst possible outcome (30-day death} to the best possible outcome (e.g. alive and free of major complications) during hospitalization and the 30-day follow-up period as defined below:
    1. 30-day death
    2. 30-day stroke
    3. 30-day life-threatening/major bleed
    4. Acute kidney injury (stage III}
    5. 30-day moderate to severe paravalvular leak
    6. None of the above
  • The TAVR 30-day mortality/morbidity composite score is reported as a "win difference" where:
    • >0 implies "My Hospital" has better than expected performance, and
    • <0 implies "My Hospital" has worse than expected performance
  • Missing value (shown as 0) indicates that the hospital does not meet eligibility criteria for reporting